Skip to main content

Articles

Page 37 of 38

  1. Canfosfamide is a novel glutathione analog activated by glutathione S-transferase P1-1. This study evaluated the safety and efficacy of canfosfamide in combination with pegylated liposomal doxorubicin (PLD) in...

    Authors: John J Kavanagh, Charles F Levenback, Pedro T Ramirez, Judith L Wolf, Carla L Moore, Marsha R Jones, Lisa Meng, Gail L Brown and Robert C Bast Jr
    Citation: Journal of Hematology & Oncology 2010 3:9
  2. Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed. Compelling evidence indicates that the immune response against ovarian cancer may play an imp...

    Authors: Bei Liu, John Nash, Carolyn Runowicz, Helen Swede, Richard Stevens and Zihai Li
    Citation: Journal of Hematology & Oncology 2010 3:7
  3. To report serial 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) tumor response following CyberKnife radiosurgery for stage IA non-small cell lung cancer (NSCLC).

    Authors: Saloomeh Vahdat, Eric K Oermann, Sean P Collins, Xia Yu, Malak Abedalthagafi, Pedro DeBrito, Simeng Suy, Shadi Yousefi, Constanza J Gutierrez, Thomas Chang, Filip Banovac, Eric D Anderson, Giuseppe Esposito and Brian T Collins
    Citation: Journal of Hematology & Oncology 2010 3:6
  4. Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and activities of transcriptional factors involved in both cancer initiation and progression through alteration of either DNA or t...

    Authors: Jiahuai Tan, Shundong Cang, Yuehua Ma, Richard L Petrillo and Delong Liu
    Citation: Journal of Hematology & Oncology 2010 3:5
  5. No standard has been established for salvage therapy in gemcitabine refractory advanced urothelial cancer. We report the complete response to FOLFOX4 therapy of a metastatic urothelial cancer patient, for whom...

    Authors: Yu Ri Seo, Se Hyung Kim, Hyun Jung Kim, Chan Kyu Kim, Seong Kyu Park, Eun Suk Koh and Dae Sik Hong
    Citation: Journal of Hematology & Oncology 2010 3:4
  6. Leser-Trélat syndrome is characterized by the eruptive appearance of multiple seborrheic keratoses in association with underlying malignant disease. Usually, the sign of Leser-Trélat is associated with adenoca...

    Authors: Giovanni Ponti, Gabriele Luppi, Lorena Losi, Alberto Giannetti and Stefania Seidenari
    Citation: Journal of Hematology & Oncology 2010 3:2
  7. Thalidomide based regimen is an effective and well tolerated therapy in multiple myeloma (MM) patients, however, there were a small number of studies written about the results of thalidomide therapy in non-tra...

    Authors: Pimjai Niparuck, Ladda Sorakhunpipitkul, Vichai Atichartakarn, Suporn Chuncharunee, Artit Ungkanont, Pantep Aungchaisuksiri, Teeraya Puavilai and Saengsuree Jootar
    Citation: Journal of Hematology & Oncology 2010 3:1
  8. We have described a severe combined immunodeficiency (SCID) mouse model that permits the subcutaneous growth of primary human acute leukemia blast cells into a measurable subcutaneous nodule which may be follo...

    Authors: Ying Yan, Eric A Wieman, Xiuqin Guan, Ann A Jakubowski, Peter G Steinherz and Richard J O'Reilly
    Citation: Journal of Hematology & Oncology 2009 2:51
  9. The last two decades have witnessed striking advances in our understanding of the biological factors underlying the development of Follicular lymphoma (FL). Development of newer treatment approaches have impro...

    Authors: Nishant Tageja, Subhash Padheye, Prasad Dandawate, Ayad Al-Katib and Ramzi M Mohammad
    Citation: Journal of Hematology & Oncology 2009 2:50
  10. The International Prognostic Index (IPI) is used to determine prognosis in diffuse large B-cell lymphoma (DLBCL). One of the determinants of IPI is the stage of disease with bone marrow involvement being class...

    Authors: Dipti Talaulikar, Bruce Shadbolt, Jane E Dahlstrom and Anne McDonald
    Citation: Journal of Hematology & Oncology 2009 2:49
  11. Pulmonary involvement and skin involvement are rare complications of plasma cell neoplasms. Here we describe what may be the first reported case of a patient with relapse in both of these sites following autol...

    Authors: Yuan Yuan, Rosemary Wieczorek, David L Green, Perry Cook, Harold Ballard and David J Araten
    Citation: Journal of Hematology & Oncology 2009 2:48
  12. Plasmablastic lymphoma (PL) is a subtype of diffuse large B-cell lymphoma (DLBCL). Studies have suggested that tumors with PL morphology represent a group of neoplasms with clinopathologic characteristics corr...

    Authors: Chung-Che Chang, Xiaobo Zhou, Jesalyn J Taylor, Wan-Ting Huang, Xianwen Ren, Federico Monzon, Yongdong Feng, Pulivarthi H Rao, Xin-Yan Lu, Facchetti Fabio, Susan Hilsenbeck, Chad J Creighton, Elaine S Jaffe and Ching-Ching Lau
    Citation: Journal of Hematology & Oncology 2009 2:47
  13. Tyrosine kinase inhibitors (TKIs) like dasatinib and nilotinib are indicated as second-line treatment for chronic myeloid leukemia resistant or intolerant to the current first-line TKI imatinib. These are agen...

    Authors: David Masiello, Gerry Gorospe III and Allen S Yang
    Citation: Journal of Hematology & Oncology 2009 2:46
  14. Recent studies have suggested that the presence of iron overload prior to stem cell transplantation is associated with decreased survival. Within these studies, the criteria used to define iron overload have v...

    Authors: Jonathan A Storey, Rebecca F Connor, Zachary T Lewis, David Hurd, Gregory Pomper, Yi K Keung, Manisha Grover, James Lovato, Suzy V Torti, Frank M Torti and István Molnár
    Citation: Journal of Hematology & Oncology 2009 2:44
  15. Activated Protein C [APC] improves outcome in immunocompetent patients with severe sepsis particularly in those who are perceived to have high mortality risk. Before embarking on a trial of APC administration ...

    Authors: Rakshit Panwar, Bala Venkatesh, Peter Kruger, Robert Bird, Devinder Gill, Leo Nunnink and Goce Dimeski
    Citation: Journal of Hematology & Oncology 2009 2:43
  16. The occurrence of chronic myeloid leukemia in pregnancy is rare and its management poses a clinical challenge for physicians treating these patients. We report a 30-year-old woman with chronic myeloid leukemia...

    Authors: Monika Conchon, Sabri S Sanabani, Israel Bendit, Fernanda Maria Santos, Mariana Serpa and Pedro Enrique Dorliac-Llacer
    Citation: Journal of Hematology & Oncology 2009 2:42
  17. Hereditary spherocytosis (HS) is a genetic disorder of the red blood cell membrane clinically characterized by anemia, jaundice and splenomegaly. Evans' syndrome is a clinical syndrome characterized by autoimm...

    Authors: Hideki Yoshida, Hiroyuki Ishida, Takao Yoshihara, Takashi Oyamada, Masataka Kuwana, Toshihiko Imamura and Akira Morimoto
    Citation: Journal of Hematology & Oncology 2009 2:40
  18. Lymphomatoid granulomatosis (LG) is a rare, Epstein-Barr virus (EBV)-associated systemic angiodestructive lymphoproliferative disorder that may progress to a diffuse large B cell lymphoma. Pulmonary involvemen...

    Authors: Ashima Makol, Kalyan Kosuri, Deimante Tamkus, Wanderley de M Calaca and Howard T Chang
    Citation: Journal of Hematology & Oncology 2009 2:39
  19. Garcinol, harvested from Garcinia indica, has traditionally been used in tropical regions and appreciated for centuries; however its biological properties are only beginning to be elucidated. There is ample data ...

    Authors: Subhash Padhye, Aamir Ahmad, Nikhil Oswal and Fazlul H Sarkar
    Citation: Journal of Hematology & Oncology 2009 2:38
  20. The general enhanced expression of α1-antichymotrypsin (ACT), clusterin (CLU), α1-antitrypsin (AAT), haptoglobin β-chain (HAP), and leucine rich glycoprotein (LRG) in the sera of patients with epithelial ovarian ...

    Authors: Yeng Chen, Boon-Kiong Lim and Onn H Hashim
    Citation: Journal of Hematology & Oncology 2009 2:37
  21. Immunomodulatory drugs lenalidomide and pomalidomide are synthetic compounds derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects. Lenalidomide is a 4-a...

    Authors: Venumadhav Kotla, Swati Goel, Sangeeta Nischal, Christoph Heuck, Kumar Vivek, Bhaskar Das and Amit Verma
    Citation: Journal of Hematology & Oncology 2009 2:36
  22. The complete pathological response after primary chemotherapy could represent an important prognostic factor in patients affected by colorectal liver metastases.

    Authors: Norma Malavasi, Giovanni Ponti, Roberta Depenni, Federica Bertolini, Sandra Zironi, Gabriele Luppi and Pier Franco Conte
    Citation: Journal of Hematology & Oncology 2009 2:35
  23. Ex vivo activation and expansion of lymphocytes for adoptive cell therapy has demonstrated great success. To improve safety and therapeutic efficacy, increased antigen specificity and reduced non-specific respons...

    Authors: Shuhong Han, Yuju Huang, Yin Liang, Yuchin Ho, Yichen Wang and Lung-Ji Chang
    Citation: Journal of Hematology & Oncology 2009 2:34
  24. The response to remission induction in elderly patients with acute myeloid leukemia (AML) remains poor. The purpose of this paper is to evaluate the efficacy and toxicity of a plant alkaloid, homoharringtonine...

    Authors: Jianmin Wang, Shuqing Lü, Jianmin Yang, Xianmin Song, Li Chen, Chongmei Huang, Jun Hou and Weiping Zhang
    Citation: Journal of Hematology & Oncology 2009 2:32
  25. Vorinostat (Zolinza®), a histone deacetylase inhibitor, was approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma...

    Authors: David Siegel, Mohamad Hussein, Chandra Belani, Francisco Robert, Evanthia Galanis, Victoria M Richon, José Garcia-Vargas, Cesar Sanz-Rodriguez and Syed Rizvi
    Citation: Journal of Hematology & Oncology 2009 2:31
  26. In the last decade the importance of ethnicity, socio-economic and gender differences in relation to disease incidence, diagnosis, and prognosis has been realized. Differences in these areas have become a majo...

    Authors: Justin P Lee, Elliott Birnstein, David Masiello, Dongyun Yang and Allen S Yang
    Citation: Journal of Hematology & Oncology 2009 2:30
  27. Advances in the treatment of chronic lymphocytic leukemia (CLL) have improved initial overall response (OR) rates, complete response (CR) rates and progression free survival (PFS). Despite these advances, CLL ...

    Authors: Kami J Maddocks and Thomas S Lin
    Citation: Journal of Hematology & Oncology 2009 2:29
  28. RIZ1 expression and activity are reduced in many cancers. In AML cell lines and patient material, RIZ1 expression is reduced relative to normal bone marrow. In chronic myelogenous leukemia (CML), blastic trans...

    Authors: Ashakumary Lakshmikuttyamma, Naoto Takahashi, Elodie Pastural, Emina Torlakovic, Hesham M Amin, Guillermo Garcia-Manero, Michael Voralia, Magdalena Czader, John F DeCoteau and C Ronald Geyer
    Citation: Journal of Hematology & Oncology 2009 2:28
  29. Rheumatoid arthritis (RA) is an autoimmune disease mediated by inflammatory processes mainly at the joints. Recently, awareness of Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder (T-LPD...

    Authors: Michihide Tokuhira, Kyoko Hanzawa, Reiko Watanabe, Yasunobu Sekiguchi, Tomoe Nemoto, Yasuo Toyozumi, Jun-ichi Tamaru, Shinji Itoyama, Katsuya Suzuki, Hideto Kameda, Shigehisa Mori and Masahiro Kizaki
    Citation: Journal of Hematology & Oncology 2009 2:27
  30. Patients suffering from adult acute lymphoblastic leukemia are acutely ill and present most commonly with fever, pallor, bleeding, lymphadenopathy, hepatosplenomegaly and presence of lymphoblasts in the periph...

    Authors: Farhat Abbas Bhatti, Iftikhar Hussain and Muhammad Zafar Ali
    Citation: Journal of Hematology & Oncology 2009 2:26
  31. Non-prescriptional use of medicinal herbs among cancer patients is common around the world. The alleged anti-cancer effects of most herbal extracts are mainly based on studies derived from in vitro or in vivo ani...

    Authors: Godfrey Chi-Fung Chan, Wing Keung Chan and Daniel Man-Yuen Sze
    Citation: Journal of Hematology & Oncology 2009 2:25
  32. The ability to screen blood of early stage operable breast cancer patients for circulating tumour cells is of potential importance for identifying patients at risk of developing distant relapse. We present the...

    Authors: Michael P Raynor, Sally-Anne Stephenson, Kenneth B Pittman, David CA Walsh, Michael A Henderson and Alexander Dobrovic
    Citation: Journal of Hematology & Oncology 2009 2:24
  33. Acute myeloid leukemia (AML) is a heterogenous disorder that results from a block in the differentiation of hematopoietic progenitor cells along with uncontrolled proliferation. In approximately 60% of cases, ...

    Authors: Tara K Gregory, David Wald, Yichu Chen, Johanna M Vermaat, Yin Xiong and William Tse
    Citation: Journal of Hematology & Oncology 2009 2:23
  34. Cisplatin depletes MGMT and increases the sensitivity of leukemia cells to temozolomide. We performed a phase I study of cisplatin and temozolomide in patients with relapsed and refractory acute leukemia. Fift...

    Authors: Karen Seiter, Sreedhar Katragadda, Doris Ponce, Muhammad Rasul and Nasir Ahmed
    Citation: Journal of Hematology & Oncology 2009 2:21
  35. Ezatiostat hydrochloride liposomes for injection, a glutathione S-transferase P1-1 inhibitor, was evaluated in myelodysplastic syndrome (MDS). The objectives were to determine the safety, pharmacokinetics, and...

    Authors: Azra Raza, Naomi Galili, Natalie Callander, Leonel Ochoa, Lawrence Piro, Peter Emanuel, Stephanie Williams, Howard Burris III, Stefan Faderl, Zeev Estrov, Peter Curtin, Richard A Larson, James G Keck, Marsha Jones, Lisa Meng and Gail L Brown
    Citation: Journal of Hematology & Oncology 2009 2:20
  36. Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology and characterized by various clinical manifestations and multiple organ involvement. It has been reported in as...

    Authors: Zhen-gang Yuan, Xiao-yi Dun, Yong-hua Li and Jian Hou
    Citation: Journal of Hematology & Oncology 2009 2:19
  37. Individualized therapies that are tailored to a patient's genetic composition will be of tremendous value for treatment of cancer. Recently, Kirsten ras (KRAS) status has emerged as a predictor of response to epi...

    Authors: David Z Chang, Vikas Kumar, Ying Ma, Kuiyuan Li and Scott Kopetz
    Citation: Journal of Hematology & Oncology 2009 2:18
  38. We studied serum proteomic profiling in patients with graft versus host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT) by two-dimensional gel electrophoresis (2-DE) and mass spec...

    Authors: Joseph McGuirk, Gang Hao, Weijian Hou, Sunil Abhyankar, Casey Williams, Weisi Yan, Jianda Yuan, Xiuqin Guan, Robert Belt, Shaun Dejarnette, Jeffery Wieman and Ying Yan
    Citation: Journal of Hematology & Oncology 2009 2:17

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here